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The Molecular Pathology of Appendiceal Neoplasms 
Amy Leeming, David Worrall, Mark J Arends 
Division of Pathology, University of Edinburgh & Pathology Department, Western General 
Hospital, Edinburgh, UK. 
Here we review the molecular pathological changes of appendiceal neoplasms, in part using 
the consensus terminology agreed by the Peritoneal Surface Oncology Group International 
(PSOGI)1,2, with appendiceal neoplasms subcategorised as: hyperplastic polyps and serrated 
lesions (with and without dysplasia); appendiceal mucinous neoplasms (low and high grade); 
adenocarcinoma; goblet cell tumours; and neuroendocrine neoplasms. Compared with 
molecular pathological studies elsewhere in the gastrointestinal tract, the neoplasms of the 
appendix are less well investigated; however correlation of molecular pathology data with 
the revised histopathological subcategorisation provides improved understanding of the 
nature of these lesions, highlights some of the differences between them, and allows 
identification of actionable mutations that may help to guide future therapy. 
 
Hyperplastic polyps and serrated lesions 
Hyperplastic polyps are non-dysplastic and comprise elongated serrated crypts with increased 
numbers of goblet cells and mucin containing columnar cells. Serrated lesions are epithelial 
polyps in which crypts are dilated and the serrated morphology extends to the crypt bases. 
Serrated lesions may be non-dysplastic or show low grade dysplasia that may take the form 
of conventional adenoma-like dysplasia, serrated-type dysplasia or traditional serrated 
adenoma-like dysplasia.  These neoplasms are usually incidental findings, although large 
lesions can be associated with acute appendicitis. Serrated lesions were historically thought 
to be similar to those seen in the colon and rectum, which appear histologically comparable. 
However, molecular data from two studies reveal differences in the nature and frequency of 
mutations in appendiceal serrated lesions compared with those arising in the colon. Yantiss 
and colleagues3 assessed a variety of genetic mutations in appendiceal serrated lesions with 
(n=23) and without (n=33) dysplasia and found similar mutation patterns in both.  BRAF and 
KRAS mutations occurred at similar frequencies of around 30%. TP53 mutations were not a 
significant feature, with only 1 mutation present (2%); and no Beta-Catenin mutations were 
found amongst this cohort. Mismatch repair protein and microsatellite instability studies 
were inconclusive. A subsequent study of appendiceal serrated lesions with and without 
dysplasia4 found a low frequency of BRAF mutations, with only 5 mutations found in 126 
lesions tested (4%). KRAS mutations were present in around 50%, with no differences found 
between non-dysplastic serrated, dysplastic serrated and non-serrated dysplastic types. 
These results contrast with the recognised serrated neoplasia pathway in the colon and 
rectum in which up to 90% of serrated lesions demonstrate BRAF mutations5. 
 
Appendiceal mucinous neoplasms (LAMN and HAMN) 
Appendiceal mucinous neoplasms are defined by the lack of an infiltrative pattern of invasion, 
although a “pushing” pattern of invasion occurs. The epithelial architecture varies, mostly 
typically a filiform / villous mucinous proliferation; while undulating, scalloped or attenuated 
monolayered appearances can also be present. The majority of these lesions show only mild 
cytological atypia and are classified as low-grade appendiceal mucinous neoplasms (LAMN). 
Lesions with a similar architectural appearance (including the lack of an infiltrative growth 
pattern) but high grade cytological atypia and increased mitotic figures are termed high-grade 
appendiceal mucinous neoplasms (HAMN). The incidence of such lesions is very low.  
Mucinous neoplasms and mucinous adenocarcinomas may give rise to pseudomyxoma 
peritonei (PMP), characterised by a progressive accumulation of mucinous ascites which may 
be acellular or contain neoplastic epithelial cells. Several studies6-11 demonstrated clonality 
and an appendiceal origin for almost all PMP1. The molecular pathology of mucinous 
neoplasms has been studied in primary appendiceal LAMNs and also in PMP lesions with an 
appendiceal origin. The reliability of studies which describe PMP as the histological diagnosis 
rather than the appendiceal histology is difficult to assess as both non–invasive (mucinous 
neoplasms) and invasive (mucinous adenocarcinoma) neoplasms of the appendix can give rise 
to PMP.  No specific data on the molecular pathology of HAMNs is found in the literature, so 
these lesions will not be considered further. 
A high frequency of KRAS mutations has consistently been found in LAMNs, although 
frequencies vary. Nishikawa and colleagues12 found KRAS activating mutations in 94% of 32 
LAMNs, while Zauber et al.13 found KRAS mutations in all 31 LAMNs studied in a cohort which 
included LAMNs and PMP lesions. A large next generation sequencing study by Borozanci and 
colleagues14 identified 83% KRAS mutations in PMP lesions. Lower frequencies have been 
found by some studies with smaller cohorts: 53% by Liu et al.15, and 27% by Hara et al.16. The 
overall frequency of KRAS mutations in LAMNs from a review of the literature was calculated 
as 78%.  
GNAS mutations are found consistently in a substantial proportion of mucinous neoplasms of 
around half, in contrast with adenocarcinomas of the appendix, with 6 studies finding 
frequencies of 35-63%6,7,12,14,15,17, although very small cohort studies have found lower 
frequencies16. 
The few next generation sequencing studies of LAMNs which have been carried out have 
allowed the recognition of lower frequencies of mutations in other neoplasia genes, including 
PIK3CA in 5-11%6,7,14,15, SMAD4 in 14-17%6,7,14, and TP53 in 5-27%6,7,16. p53 protein was 
overexpressed in 44%8. A single case with an AKT1 mutation was found in the cohorts of 3 
studies6,7,15. APC mutations were not found in any of 4 studies6,7,13,14, but Liu and colleagues15 
found a small number of cases with mutated APC. Microsatellite instability has not been found 
in any study7,13. 
In summary, LAMNs are microsatellite stable and carry frequent KRAS and GNAS mutations 
with small numbers carrying a range of other mutations in cancer genes. 
 
Adenocarcinoma 
Appendiceal adenocarcinomas are defined by the presence of infiltrative invasion and include 
mucinous and signet ring subtypes2. Molecular studies of appendiceal adenocarcinomas have, 
to varying degrees, subcategorised cases by tumour grade or pattern (mucinous and/or signet 
ring adenocarcinomas). Most of these studies predate the more recent diagnostic guidance, 
giving rise to some inconsistencies in nomenclature. The molecular profiles differ significantly 
based on tumour subtype for some mutation loci. 
KRAS mutations appear in around half of all adenocarcinomas. The largest NGS study by 
Borozanci and colleagues14 comprised 442 adenocarcinomas, with KRAS mutations present in 
55% of adenocarcinomas overall. 65% of the cases categorised as mucinous adenocarcinomas 
demonstrated KRAS mutation, compared to 47% of intestinal-type adenocarcinomas and only 
7% of signet ring cell adenocarcinomas, implying different molecular profiles between the 
subtypes. A much smaller study15 found KRAS mutations in 6 of 8 well differentiated 
adenocarcinomas associated with PMP and no mutations in 11 signet ring adenocarcinomas.  
GNAS mutations are also present at a lower rate in adenocarcinomas than in LAMNs, with an 
overall combined mutation frequency of 16%, including 30% of mucinous adenocarcinomas 
and 6% of non-mucinous adenocarcinomas12,15,17. BRAF mutations were found in 8% of 
appendiceal adenocarcinomas14, less frequently than in the colorectum, where mutations are 
present in 9-22% of tumours18-20. 
Mutations of the TP53 gene appear to be present in approximately a quarter of appendiceal 
adenocarcinomas, with concordant frequencies of 24%-26% TP53 mutations across subtypes 
found in two studies15,21. NGS analysis of mucinous, intestinal-type and signet ring 
adenocarcinoma demonstrated comparable TP53 mutation frequencies of 24%, 32% and 15% 
respectively14. 
  
APC mutations also appear at significant frequencies in some subtypes:  7% in mucinous 
adenocarcinomas (n=317), 32% in intestinal-type adenocarcinomas (n=82) and 15% in signet 
ring cell adenocarcinomas (n=43). Liu et al.15 found APC mutations in 27% of adenocarcinomas 
with goblet cells but none in well differentiated adenocarcinomas associated with PMP. 
However Jesinghaus and colleagues21 found only 1 APC mutation within a colorectal type 
adenocarcinoma among 25 mixed adenocarcinomas of the appendix.  
In contrast to mucinous neoplasms, which consistently show no evidence of microsatellite 
instability (MSI), small numbers of adenocarcinomas of the appendix have been found to 
show high levels of microsatellite instability (MSI): 2 of 35 (6%) by Raghav et al.22 and 3 of 96 
cases (3%) by Taggart et al.23. In contrast, no adenocarcinomas with MSI were found by 
Jesinghaus et al.21, 2018 (n=25), Borozanci et al.14 (n=588), or Kabbani et al.24 (n=30). The 
defective mismatch repair pathway of carcinogenesis appears less numerically important in 
the appendix than in the colorectum.  
 
Goblet cell adenocarcinoma 
Goblet cell adenocarcinomas (GCAs) are amphicrine tumours comprising cells with secretory 
phenotypes, including goblet cells, Paneth cells and endocrine cells, growing in tubules, small 
clusters, sheets or single infiltrative cells. Goblet cell adenocarcinomas have undergone 
significant reclassification over time, originally being classified as a carcinoid subtype, goblet 
cell carcinoid (GCC). The more aggressive phenotypes were given the designation 
‘adenocarcinoma ex goblet cell carcinoid’ or ‘mixed adeno-neuroendocrine carcinoma’ in the 
2010 WHO classification25.  
Recent molecular data now indicates these tumours are a distinctly different group from both 
neuroendocrine tumours (NETs) and adenocarcinomas (ACs)21,26,27. Sequencing studies 
analysed a series of GCCs and adenocarcinoma ex carcinoids (AC-EC), in addition to NETs and 
ACs21,26 and found that GCC and AC-EC are best interpreted as a single morphomolecular 
entity, distinct from NETs and ACs. GCCs and AC-ECs demonstrated mutations in the WNT-
signalling pathway genes USP9X, NOTCH1, CTNNA1, CTNNB1, and TRRAP; and in 
chromatin remodelling genes ARID1A, ARID2, KDM6A, and KMT2D/MLL221,26,27. In contrast 
to the recognised tumourigenesis of colorectal adenocarcinomas, few or no mutations were 
found in TP53, KRAS, SMAD4 and APC genes and all cases were microsatellite stable. This data 
is in agreement with previous studies of GCCs that also found a lack of microsatellite 
instability23,28 and of KRAS mutations28-30. P53 protein overexpression has not been found by 
some studies29,31, although mutations in TP53 in 4 of 16 cases (25%) were found by Ramnani 
et al.30. Allelic loss has been found at 18q (56%) 16q (38%) 11q (25%) and 6q (83%) in these 
tumours26,29. Some intestinal neuroendocrine tumours have also shown allelic changes at 
these and other loci (8q, 4p), but do not show the mutation pattern seen in GCCs and AC-ECs. 
Yozu et al.32 presented a reclassification of this new combined entity as goblet cell 
adenocarcinoma (GCA) and proposed a grading system based on the overall proportion of 
tubular architecture.  
 
Neuroendocrine neoplasms 
Neuroendocrine lesions of the appendix are defined by the presence of cytoplasmic 
neurosecretory granules or microvesicles and comprise well differentiated neuroendocrine 
tumours (NETs), neuroendocrine carcinomas (NECs) and mixed neuroendocrine-non 
neuroendocrine tumours (MiNENs). The entity previously included in this category as goblet 
cell carcinoid has been recategorised as goblet cell adenocarcinoma, as previously discussed.  
Appendiceal NETs are of 3 subtypes, Enterochromaffin cell (EC), L-cell and tubular NET. Most 
are grade 1 and have good long-term survival. NECs are rare and no published molecular data 
is currently available. Tubular NETs may be a variant of L-cell NETs and tend to follow a benign 
course. MiNENs should contain by definition at least 30% each of neuroendocrine and non-
neuroendocrine components. No specific molecular data was found relating to MiNENs, 
reflecting its recent description. 
The molecular profile of NETs is not well established, although these tumours do not seem to 
harbour the mutational changes seen in other appendiceal or colorectal neoplasms. The large 
scale NGS study by Borazanci et al.14 sequenced 81 neuroendocrine tumours and found an 
overall lower mutational rate than other the entities sequenced. KRAS mutations were found 
in 9%, GNAS in 3%, mutations in SMAD4 in 13% and TP53 mutations in 11%. These results 
contrast with those seen by Ramnani et al.30 who used conventional and less sensitive 
sequencing of KRAS and TP53 genes in 18 typical carcinoids and found no KRAS mutations but 
TP53 mutations in 44%. 3 NETs were sequenced as a reference comparator in a further 
study26, and no somatic coding mutations, copy number changes or pathogenic germline 
alterations were found. 
 Major Molecular profile* 
Serrated lesions BRAF 4-30% 
KRAS 31-52% 
LAMN 
KRAS 78% 
GNAS 49% 
PIK3CA 5-11%; SMAD4 14-17%; TP53 2-27% 
Microsatellite stable 
Adenocarcinoma 
KRAS 53% 
GNAS 16% 
TP53 24-26% 
APC up to 32% with subtype 
Microsatellite instability in <6% 
GCC Loss of heterozygosity at 18q,16q, 11q and 6q 
USP9X, NOTCH1, CTNNA1, CTNNB1, and TRRAP 
ARID1A, ARID2, KDM6A, and KMT2D/MLL2 
Neuroendocrine 
neoplasms TP53 11-44% 
Table 1. Overview of mutational profiles of appendiceal neoplasms (*mutation frequency in stated neoplasia 
gene, unless otherwise stated). 
Discussion 
Appendiceal neoplasms are not common, not extensively studied, and have undergone 
multiple reclassifications and nomenclature changes, all of which hamper attempts to collate 
the available molecular pathology data. In addition, published histopathological details of 
tumours that were molecularly analysed are often scant, and it is therefore likely that 
reported diagnostic categories include cases which would currently be subtyped differently. 
Despite this, mutational profiles have recently been instrumental in defining the current 
diagnostic criteria, for example, as defining goblet cell carcinomas as an entity in their own 
right rather than as a subtype of either neuroendocrine tumours or adenocarcinomas. The 
wealth of literature on the molecular pathology of colorectal neoplasms allows comparison 
with entities in the appendix, and many appendiceal lesions appear to be unique to this 
location.  Adenocarcinoma of the appendix, although morphologically comparable to 
adenocarcinoma of the colorectum, appears to show a different molecular profile, with lower 
rates of microsatellite instability and BRAF mutations. Some recognised histopathological 
entities such as HAMN, hyperplastic polyps, neuroendocrine carcinomas and MiNEN are even 
less well molecularly profiled, usually due to rarity, but future molecular pathology data may 
help to further characterise these lesions. 
  
 
 
 
 
 
 
References 
1. Carr NJ, Cecil TD, Mohamed F, et al. Peritoneal Surface Oncology Group International. A 
Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and 
Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group 
International (PSOGI) Modified Delphi Process.  Am J Surg Pathol. 2016 Jan;40(1):14-26.  
2. Carr NJ, Bibeau F, Bradley RF, et al. The histopathological classification, diagnosis and 
differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas 
and pseudomyxoma peritonei. Histopathology. 2017;71(6):847-858.  
3. Yantiss RK, Panczykowski A, Misdraji J, et al. A comprehensive study of nondysplastic and 
dysplastic serrated polyps of the vermiform appendix. Am J Surg Pathol. 2007 
Nov;31(11):1742-53.  
4. Pai RK, Hartman DJ, Gonzalo DH, et al. Serrated lesions of the appendix frequently harbor 
KRAS mutations and not BRAF mutations indicating a distinctly different serrated 
neoplastic pathway in the appendix. Hum Pathol. 2014 Feb;45(2):227-35. 
5. Carr NJ, Mahajan H, Tan KL et al. Serrated and non-serrated polyps of the colorectum: their 
prevalence in an unselected case series and correlation of BRAF mutation analysis with the 
diagnosis of sessile serrated adenoma. J Clin Pathol. 2009 Jun;62(6):516-8. 
6. Noguchi R, Yano H, Gohda Y, et al. Molecular profiles of high-grade and low-grade 
pseudomyxoma peritonei. Cancer Med. 2015 Dec;4(12):1809-16.  
7. Nummela P, Saarinen L, Thiel A, et al. Genomic profile of pseudomyxoma peritonei 
analyzed using next-generation sequencing and immunohistochemistry. Int J Cancer. 2015 
Mar 1;136(5):E282-9.  
8. Shetty S, Thomas P, Ramanan B, et al. Kras mutations and p53 overexpression in 
pseudomyxoma peritonei: association with phenotype and prognosis. J Surg Res. 2013 
Mar;180(1):97-103.  
9. Chuaqui RF, Zhuang Z, Emmert-Buck MR, et al. Genetic analysis of synchronous mucinous 
tumors of the ovary and appendix. Hum Pathol. 1996 Feb;27(2):165-71. 
10. Cuatrecasas M, Matias-Guiu X, Prat J. Synchronous mucinous tumors of the appendix and 
the ovary associated with pseudomyxoma peritonei. A clinicopathologic study of six cases 
with comparative analysis of c-Ki-ras mutations. Am J Surg Pathol. 1996 Jun;20(6):739-46.  
11. Szych C, Staebler A, Connolly DC, et al. Molecular genetic evidence supporting the clonality 
and appendiceal origin of Pseudomyxoma peritonei in women. Am J Pathol. 1999 
Jun;154(6):1849-55.  
12. Nishikawa G, Sekine S, Ogawa R, et al. Frequent GNAS mutations in low-grade appendiceal 
mucinous neoplasms. Br J Cancer. 2013 Mar 5;108(4):951-8.  
13. Zauber P, Berman E, Marotta S, et al. Ki-ras gene mutations are invariably present in low-
grade mucinous tumors of the vermiform appendix. Scand J Gastroenterol. 2011 Jul;46(7-
8):869-74.  
14. Borazanci E, Millis SZ, Kimbrough J, et al. Potential actionable targets in appendiceal cancer 
detected by immunohistochemistry, fluorescent in situ hybridization, and mutational 
analysis. J Gastrointest Oncol. 2017;8(1):164-172.  
15. Liu X, Mody K, de Abreu FB, et al. Molecular profiling of appendiceal epithelial tumors 
using massively parallel sequencing to identify somatic mutations. Clin Chem. 2014 
Jul;60(7):1004-11. 
16. Hara K, Saito T, Hayashi T, et al. A mutation spectrum that includes GNAS, KRAS and TP53 
may be shared by mucinous neoplasms of the appendix. Pathol Res Pract. 2015 
Sep;211(9):657-64.  
17. Singhi AD, Davison JM, Choudry HA, et al. GNAS is frequently mutated in both low-grade 
and high-grade disseminated appendiceal mucinous neoplasms but does not affect 
survival. Hum Pathol. 2014 Aug;45(8):1737-43.  
18. Ahlquist T, Bottillo I, Danielsen SA, et al. RAS signaling in colorectal carcinomas through 
alteration of RAS, RAF, NF1, and/or RASSF1A. Neoplasia. 2008;10(7):680-6. 
19. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and 
mismatch-repair status. Nature. 2002 Aug 29;418(6901):934.  
20. Garnett MJ and Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 2004 
Oct;6(4):313-9. 
21. Jesinghaus M, Konukiewitz B, Foersch S, et al. Appendiceal goblet cell carcinoids and 
adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-
type adenocarcinoma of the appendix. Mod Pathol. 2018 May;31(5):829-839.  
22. Raghav KP, Shetty AV, Kazmi SM. Impact of molecular alterations and targeted therapy in 
appendiceal adenocarcinomas. Oncologist. 2013;18(12):1270-7. Dimmler A, Geddert H, 
Faller G. EGFR, KRAS, BRAF-mutations and microsatellite instability are absent in goblet cell 
carcinoids of the appendix. Pathol Res Pract. 2014 May;210(5):274-8.  
23. Taggart MW, Galbincea J, Mansfield PF, et al. High-level microsatellite instability in 
appendiceal carcinomas. Am J Surg Pathol. 2013 Aug;37(8):1192-200.  
24. Kabbani W, Houlihan PS, Luthra R, et al. Mucinous and nonmucinous appendiceal 
adenocarcinomas: different clinicopathological features but similar genetic alterations. 
Mod Pathol. 2002 Jun;15(6):599-605.  
25. Komminoth P, Arnold R, Capella C et al. Neuroendocrine neoplasms of the appendix. In: 
Bosman F, Carneiro F, Hruban R et al eds. WHO Classifocation of Tumours of the Digestive 
System. WHO Press; 2010:126-128. 
26. Wen KW, Grenert JP, Joseph NM, et al. Genomic profile of appendiceal goblet cell 
carcinoid is distinct compared to appendiceal neuroendocrine tumor and conventional 
adenocarcinoma. Hum Pathol. 2018 Jul;77:166-174.  
27. Johncilla M, Stachler M, Misdraji J, et al. Mutational landscape of goblet cell carcinoids and 
adenocarcinoma ex goblet cell carcinoids of the appendix is distinct from typical carcinoids 
and colorectal adenocarcinomas. Mod Pathol. 2018 Jun;31(6):989-996. 
28. Dimmer A, Geddert H, Faller G. EGFR, KRAS, BRAF-mutations and microsatellite instability 
are absent in goblet cell carcinoids of the appendix. Pathol Res Pract. 2014 May; 
210(5):274-8.  
29. Stancu M, Wu TT, Wallace C, et al. Genetic alterations in goblet cell carcinoids of the 
vermiform appendix and comparison with gastrointestinal carcinoid tumors. Mod Pathol. 
2003 Dec;16(12):1189-98. 
30. Ramnani DM, Wistuba II, Behrens C, et al. K-ras and p53 mutations in the pathogenesis of 
classical and goblet cell carcinoids of  the appendix. Cancer. 1999 Jul 1;86(1):14-21.  
31. van Eeden S, Offerhaus GJ, Hart AA, et al. Goblet cell carcinoid of the appendix: a specific 
type of carcinoma. Histopathology. 2007 Dec;51(6):763-73.  
32. Yozu M, Johncilla ME, Srivastava A, et al. Histologic and Outcome Study Supports 
Reclassifying Appendiceal Goblet Cell Carcinoids as Goblet Cell Adenocarcinomas,  and 
Grading and Staging Similarly to Colonic Adenocarcinomas. Am J Surg Pathol. 2018 
Jul;42(7):898-910.  
 
